Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new randomized trial shows that adding catheter-directed thrombolysis to standard anticoagulation slashes the risk of death, recurrent clots, or cardiorespiratory collapse by 90% in intermediate-high-risk pulmonary embolism patients. The PRAGUE-26 trial, published in the NEJM, found the procedure is safe, requires no specialized equipment, and can be performed in any existing cath lab — potentially transforming how PE care is organized worldwide.
Pulmonary embolism (PE) has long been managed the same way for decades — anticoagulation, and systemic thrombolysis only when things go south. The PRAGUE-26 trial, presented at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine, is pushing for a major upgrade. The randomized trial found that adding catheter-directed thrombolysis with alteplase to standard anticoagulation reduced the composite risk of death, recurrent PE, or cardiorespiratory decompensation by a relative 90% within 7 days in intermediate-high-risk PE patients.
What makes this especially noteworthy? The procedure doesn't require ultrasound guidance or specialized equipment — just standard cath lab infrastructure and a short learning curve. Investigators emphasized that any interventional cardiologist worldwide could perform it, opening the door to much wider adoption than previously thought possible.
By the Numbers
Why it matters: PE patients are often scattered across hospital wards with little centralized care — unlike STEMI or stroke. PRAGUE-26 makes a compelling case that interventional treatment should become the standard for intermediate-high-risk PE, and that existing infrastructure can make that shift feasible now.
